Tirzepatide Guidelines for Overweight Adults without Diabetes

Eligibility and Indications

Adults with a body‑mass index ≥ 27 kg/m² and at least one weight‑related comorbidity (e.g., dyslipidemia) satisfy the FDA‑approved criteria for tirzepatide therapy. 1
In non‑diabetic patients with obesity, tirzepatide 15 mg weekly yields a mean weight loss of approximately 20.9 % after 72 weeks. 1

Absolute contraindications are a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2). 1
Stable normal‑variant optic‑nerve cupping is not listed as a contraindication for tirzepatide or other GLP‑1 receptor agonists. 1
Diabetes is a risk factor for glaucoma progression but not a contraindication to GLP‑1‑based therapy. 2
Common gastrointestinal adverse events occur in 17‑22 % (nausea), 13‑16 % (diarrhea), and 6‑10 % (vomiting) of patients; a gradual 4‑week titration schedule reduces their incidence. 1
Rare serious adverse events include pancreatitis (monitor for persistent severe abdominal pain) and gallbladder disease (monitor for right‑upper‑quadrant pain). 1

Initiate tirzepatide at 2.5 mg weekly for weeks 0‑4 (tolerability phase), then increase to 5 mg weekly for weeks 5‑8 (first therapeutic dose).
Continue titration to 7.5 mg weekly (weeks 9‑12), 10 mg weekly (weeks 13‑16), and up to 12.5‑15 mg weekly for maximal efficacy. 1

Approximately 57 % of patients achieve ≥20 % weight loss with the 15 mg dose; 91 % achieve ≥5 % weight loss. 1
Tirzepatide provides superior triglyceride reduction and overall improvement in lipid profiles compared with other weight‑loss agents. 1
Blood‑pressure reductions are observed through multiple mechanisms, contributing to cardiovascular risk mitigation. 1

During titration, assess gastrointestinal tolerance, weight change, and blood pressure every 4 weeks. 1
At 12‑16 weeks on a therapeutic dose, confirm ≥5 % weight loss to justify continuation of therapy. 1
After reaching a maintenance dose, perform weight, blood pressure, lipid panel, and adherence assessments every 3 months. 1

Discontinue tirzepatide if weight loss is < 5 % after 3‑4 months on a therapeutic dose (≥5 mg). 1
Stop the medication in the presence of pancreatitis, gallbladder disease requiring intervention, or intolerable gastrointestinal side effects despite dose adjustment. 1

Tirzepatide therapy should be combined with a 500‑kcal daily deficit diet and at least 150 minutes of moderate‑intensity physical activity per week. 1
Expected cost is approximately $1,272 per 30‑day supply. 1

Required documentation: BMI ≥ 27 kg/m² with a weight‑related comorbidity, documented failed lifestyle‑modification attempts, baseline lipid panel, and a statement linking weight loss to cardiovascular‑risk reduction.
Approval rates are 65‑75 % on the first prior‑authorization request and rise to 85‑90 % after appeal. 3

Adults with a body‑mass index (BMI) ≥ 30 kg/m² are eligible for tirzepatide therapy without the need for additional weight‑related comorbidities, according to the 2023 JAMA publication. 4

Tirzepatide achieves the greatest mean percentage weight loss among currently approved anti‑obesity agents, as demonstrated in the 2023 JAMA trial. 4
In the same trial, a 15 mg weekly dose produced a mean weight reduction of 20.9 % after 72 weeks of treatment. 4
Compared with semaglutide 2.4 mg (which yielded a mean weight loss of 14.9 %), tirzepatide demonstrated superior efficacy. 4

Constipation was reported in approximately 5 % of patients receiving tirzepatide in the 2023 JAMA study. 4